| Title: | PCSK9 genetic variants and cognitive abilities: a large-scale Mendelian randomization study |
| Journal: | Arch Med Sci |
| Published: | 5 Jan 2021 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/33488877/ |
| DOI: | https://doi.org/10.5114/aoms/127226 |
Publication 3405
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
PCSK9 inhibitors are an effective medication for lowering low-density lipoprotein levels, and their use has been associated with lower risk of poor cardiometabolic health. Some questions remain from trial data, however, relating to whether their use may have cognitive side-effects (e.g. memory). We used genetic variation in the PCSK9 gene to mimic use of these inhibitors in generally healthy middle-aged to older adults. We found limited evidence of association between the PCSK9 genetic risk score and worse cognitive scores; overall, pharmacovigilance is recommended.1 Author
- Lyall DM et al.
1 Application
| Application ID | Title |
|---|---|
| 17689 | Genetic, environmental and lifestyle predictors of brain/cognitive-related outcomes. |
Enabling scientific discoveries that improve human health